Emerging immunotherapies for AML

preview_player
Показать описание
Naval Daver, MD, University of Texas MD Anderson Cancer Center, Houston, TX, outlines the emerging immunotherapies for acute myeloid leukemia (AML). Specifically, T-cell enhancing therapies, macrophage-enhancing agents, bispecific antibodies and CAR-T cells are discussed. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
  1. VJHemOnc – Video Journal of Hematology & HemOnc
  2. Speaker: Naval Daver
  3. Event: VJVirtual
  4. Format: Interview
  5. Subject: Leukemia
  6. Subject: Acute Myeloid Leukemia
Рекомендации по теме
Emerging immunotherapies for 0:04:54

Emerging immunotherapies for AML

What’s new in 0:05:15

What’s new in immunotherapy for AML?

Emerging immunotherapy modalities 0:04:31

Emerging immunotherapy modalities in AML and exciting data from ASH 2019

New research areas 0:01:45

New research areas in the treatment of AML

Immunotherapy for AML 0:07:54

Immunotherapy for AML

Immunotherapy for pediatric 0:05:17

Immunotherapy for pediatric AML

Emerging therapies in 0:02:04

Emerging therapies in AML: why patients should be optimistic

Immunotherapy for AML 0:07:40

Immunotherapy for AML and ALL: checkpoint inhibitors & CAR T-cells for B-cell ALL

What is immunotherapy 0:03:04

What is immunotherapy for AML?

New treatments for 0:01:19

New treatments for AML

New immunotherapy for 0:03:26

New immunotherapy for leukemia shows promise in small clinical trial

New developments in 0:01:54

New developments in AML treatment

Final Thoughts on 0:04:10

Final Thoughts on Emerging Therapies for AML

Key challenges in 0:01:12

Key challenges in immunotherapy for AML

Acute Myeloid Leukemia 0:38:47

Acute Myeloid Leukemia

Developments in therapies 0:04:20

Developments in therapies for AML - chemotherapy, targeted therapy and immunotherapy

Emerging Targeted Agents 0:04:26

Emerging Targeted Agents in AML

Significance of Minimal 0:58:32

Significance of Minimal Residual Disease in Acute Myeloid Leukemia

Immunotherapy for AML 0:11:19

Immunotherapy for AML & ALL

Current and emerging 0:02:21

Current and emerging treatment strategies for post-MPN AML

Immunotherapy in AML: 0:02:41

Immunotherapy in AML: azacitidine plus checkpoint inhibitors

2021 New and 1:31:30

2021 New and Emerging Treatment Options: AML and Minimal Residual Disease in Blood Cancers

What new treatments 0:02:58

What new treatments are in development for AML?

Session highlights: transforming 0:02:38

Session highlights: transforming AML treatment and building on new approaches